Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells

Blood

Volumn 96, Issue 9, 2000, Pages 3195-3199

  Thiesing, J Tyler ^a   Ohno Jones, Sayuri ^a   Kolibaba, Kathryn S ^a   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0034330931     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.3195.h8003195_3195_3199     Document Type: Article

References (26)

1. The molecular genetics of Philadelphia chromosome-positive leukemias
2. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
3. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration
4. The biology of chronic myeloid leukemia
5. Chronic myeloid leukemia
6. Treatment of chronic myeloid leukaemia: Some topical questions
7. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
8. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
9. Interferon alfa-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia
10. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group
11. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients
12. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
13. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
14. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
15. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
16. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
17. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features
18. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL
19. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome
20. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
21. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
22. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of Bcr-Abl-positive cells
23. + leukemic cells and induces apoptosis
24. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
25. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
26. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl